PRISM is a novel initiative announced by The National PERT Consortium in October 2025, aiming to disseminate the pulmonary embolism response team (PERT) concept and further enhance care for patients. The PERT model has transformed acute PE management by introducing rapid, coordinated, multidisciplinary decision-making for a complex and life-threatening condition. Building on this foundation, PRISM represents the next evolution, ensuring that excellence in PE care is not only achieved in moments of crisis, but sustained, measured, and continuously improved over time. PRISM unifies education, outreach, standards, data, and outcomes into a single, integrated framework designed to advance every facet of PE care.

PRISM brings clarity to a fragmented care landscape. Through a multidisciplinary approach that spans clinicians, researchers, educators, and health care systems, PRISM illuminates best practices and elevates performance across the full continuum of PE care—from recognition and acute management to recovery and long-term outcomes. Rather than focusing on isolated interventions, PRISM aims to align mission, vision, and action to create a learning health care ecosystem dedicated to measurable improvement.

PRISM’s mission is to advance the quality and effectiveness of PE care by integrating research, continuous quality improvement, and standardized practices that optimize outcomes for every patient. Its vision is a global health care community where shared standards, collaborative learning, and real-world data drive the highest level of PE care everywhere. Together, these principles guide PRISM’s work across six interconnected focus areas.

Quality is foundational. PRISM establishes a robust quality assurance infrastructure for PE care providers, enabling standardized metrics, benchmarking, and performance dashboards that allow teams to assess performance and identify opportunities for improvement. Standards further reinforce excellence by defining, updating, and implementing evidence-based best practices. Through aligned clinical pathways and guideline-driven care, PRISM promotes consistency while allowing flexibility for patient-centered decision-making.

Outcomes remain the ultimate measure of success. PRISM emphasizes the use of real-world data to track and improve patient-centered results, including mortality, recurrence, recovery, and long-term health. These data also fuel the research focus area, where multicenter collaboration and outcomes science drive discovery, innovation, and publication through registry-based research efforts.

Education and outreach ensure that knowledge translates into action. PRISM empowers the PE community through live programming, interactive learning, online education, and professional networking. Outreach efforts expand awareness of PE through community campaigns, advocacy, and stakeholder engagement, bridging the gap between clinical excellence and public understanding.

Beyond these core pillars, PRISM provides open access to PE Centers of Excellence certification and the PERC Quality Assurance Database, establishes standards of care grounded in real-world evidence and landmark studies, and expands educational resources and programming. Through initiatives such as the PERT Partners Program, publications, and community engagement, PRISM actively supports the broader ecosystem of PE care stakeholders.

From mission to milestones, PRISM represents a collaborative commitment to advancing PE care—transforming data into insight, standards into practice, and collaboration into better outcomes for patients everywhere.

Michelle Lanno is CEO of PERT Consortium; Mahir Elder, MD, is with Wayne State University School of Medicine in Detroit, Michigan, and President of PERT Consortium; Seth Sokol, MD, is with Montefiore Einstein in Bronx, New York, and Board Chair of PERT Consortium; and Kenneth Rosenfield, MD, MHCDS, is with Massachusetts General Hospital in Boston, Massachusetts, and Founder, of PERT Consortium.

Disclosures: Ms. Lanno, None; Dr. Elder, unavailable at the time of publication; Dr. Sokol, None; Dr. Rosenfield, consultant/scientific advisory board for Abbott Vascular, AngioDynamics, Boston Scientific Corporation, Cordis, Johnson & Johnson, Biosense Webster, Medtronic, NAMSA, Philips, and Salus Scientific; consulting with equity/stock options in Akura, Contego Medical, Fastwave, Imperative Care, Innova Vascular, InspireMD, Jupiter, Magneto, Radiaction, SonoVascular, Vantis Vascular, and Viz.ai..